An observational analysis showed a long-term OS benefit with Orca-T in adult patients undergoing allogeneic transplantation for hematologic malignancies.
|Videos|July 25, 2011
Reynaldo Garcia on CML BCR-ABL Testing
Author(s)Reynaldo Garcia, RN, OCN
Reynaldo Garcia From Lineberger Comprehensive Cancer Center on CML BCR-ABL Testing Recommendation
Advertisement
Reynaldo Garcia, RN, OCN®, Lineberger Comprehensive Cancer Center—Protocol Office, University of North Carolina at Chapel Hill on CML BCR-ABL Testing Recommendation
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in NSCLC, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Mosunetuzumab plus lenalidomide met the CELESTIMO trial's primary end point, improving PFS in relapsed/refractory follicular lymphoma.
A PET-guided, nivolumab-based regimen produced promising response rates in advanced-stage classical Hodgkin lymphoma.
The FDA set a target action date of June 29, 2027, for bezuclastinib's NDA in advanced systemic mastocytosis, backed by APEX trial data.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
3
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
4
Dr Voorhees on Eligibility Criteria for the CERVINO Trial in Multiple Myeloma
5